Original Article

You have full text access to this OnlineOpen article

The role of angiocidin in sarcomas

  1. Catherine Liebig MD1,
  2. Jonathan A. Wilks MD1,
  3. Barry W. Feig MD2,
  4. Thomas N. Wang MD, PhD3,
  5. Mariya Wilson BS3,
  6. Ann V. Herdman MD4,
  7. Daniel Albo MD, PhD1,†,*

Article first published online: 24 JUL 2009

DOI: 10.1002/cncr.24568

Issue

Cancer

Cancer

Volume 115, Issue 22, pages 5251–5262, 15 November 2009

Additional Information

How to Cite

Liebig, C., Wilks, J. A., Feig, B. W., Wang, T. N., Wilson, M., Herdman, A. V. and Albo, D. (2009), The role of angiocidin in sarcomas. Cancer, 115: 5251–5262. doi: 10.1002/cncr.24568

Author Information

  1. 1

    Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas

  2. 2

    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  3. 3

    Department of Surgery, Medical College of Georgia, Augusta, Georgia

  4. 4

    Department of Pathology, Medical College of Georgia, Augusta, Georgia

  1. †

    Fax: (713) 794-7352

*Michael E. DeBakey Department of Surgery, Baylor College of Medicine, 2002 Holcombe Boulevard, OCL 112A, Houston, TX 77030

Publication History

  1. Issue published online: 3 NOV 2009
  2. Article first published online: 24 JUL 2009
  3. Manuscript Accepted: 8 APR 2009
  4. Manuscript Revised: 4 APR 2009
  5. Manuscript Received: 23 DEC 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (626K)

References

  • 1
    Perez-Mancera PA, Sanchez-Garcia I. Understanding mesenchymal cancer: the liposarcoma-associated FUS-DDIT3 fusion gene as a model. Semin Cancer Biol. 2005; 15: 206-214.
  • 2
    Schlieman M, Smith R, Kraybill WG. Adjuvant therapy for extremity sarcomas. Curr Treat Options Oncol. 2006; 7: 456-463.
  • 3
    Seynaeve C, Verweij J. High-dose chemotherapy in adult sarcomas: no standard yet. Semin Oncol. 1999; 26: 119-133.
  • 4
    Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001; 19: 1238-1247.
  • 5
    Tierney JF, Mosseri V, Stewart LA, Souhami RL, Parmar MK. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials. Br J Cancer. 1995; 72: 469-475.
  • 6
    Balasubramanian L, Evens AM. Targeting angiogenesis for the treatment of sarcoma. Curr Opin Oncol. 2006; 18: 354-359.
  • 7
    Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006; 28: 1779-1802.
  • 8
    Yang X, Rothman VL, L'Heureux DZ, Tuszynski G. Reduction of angiocidin expression in human umbilical vein endothelial cells via siRNA silencing inhibits angiogenesis. Exp Mol Pathol. 2006; 81: 108-114.
  • 9
    Zhou J, Rothman VL, Sargiannidou I, et al. Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1. J Cell Biochem. 2004; 92: 125-146.
    Direct Link:
  • 10
    Sabherwal Y, Rothman VL, Dimitrov S, et al. Integrin alpha2beta1 mediates the anti-angiogenic and anti-tumor activities of angiocidin, a novel tumor-associated protein. Exp Cell Res. 2006; 312: 2443-2453.
  • 11
    Sabherwal Y, Rothman VL, Poon RT, Tuszynski GP. Clinical significance of serum angiocidin levels in hepatocellular carcinoma. Cancer Lett. 2007; 251: 28-35.
  • 12
    Roth JJ, Buckmire MA, Rolandelli RH, Granick MS, Tuszynski GP. Localization of thrombospondin-1 and its cysteine-serine-valine-threonine-cysteine-glycine receptor in colonic anastomotic healing tissue. Histol Histopathol. 1998; 13: 967-971.
  • 13
    Roth JJ, Sung JJ, Granick MS, et al. Thrombospondin 1 and its specific cysteine-serine-valine-threonine-cysteine-clycine receptor in fetal wounds. Ann Plast Surg. 1999; 42: 553-563.
  • 14
    Poon RT, Chung KK, Cheung ST, et al. Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin Cancer Res. 2004; 10( 12 pt 1): 4150-4157.
  • 15
    Tuszynski GP, Rothman VL, Papale M, Hamilton BK, Eyal J. Identification and characterization of a tumor cell receptor for CSVTCG, a thrombospondin adhesive domain. J Cell Biol. 1993; 120: 513-521.
  • 16
    Albo D, Shinohara T, Tuszynski GP. Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer. J Surg Res. 2002; 108: 51-60.
  • 17
    Tuszynski GP, Rothman VL, Deutch AH, Hamilton BK, Eyal J. Biological activities of peptides and peptide analogues derived from common sequences present in thrombospondin, properdin, and malarial proteins. J Cell Biol. 1992; 116: 209-217.
  • 18
    Tuszynski GP, Srivastava S, Switalska HI, Holt JC, Cierniewski CS, Niewiarowski S. The interaction of human platelet thrombospondin with fibrinogen. Thrombospondin purification and specificity of interaction. J Biol Chem. 1985; 260: 12240-12245.
  • 19
    Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J Biol Chem. 1994; 269: 26775-26782.
  • 20
    Sargiannidou I, Qiu C, Tuszynski GP. Mechanisms of thrombospondin-1-mediated metastasis and angiogenesis. Semin Thromb Hemost. 2004; 30: 127-136.
  • 21
    Nicosia RF, Tuszynski GP. Matrix-bound thrombospondin promotes angiogenesis in vitro. J Cell Biol. 1994; 124: 183-193.
  • 22
    Albini A. Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res. 1998; 4: 230-241.
  • 23
    Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 1987; 47: 3239-3245.
  • 24
    Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin. 1998; 48: 6-29.
    Direct Link:
  • 25
    Albo D, Berger DH, Tuszynski GP. The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion. J Surg Res. 1998; 76: 86-90.
  • 26
    Albo D, Berger DH, Vogel J, Tuszynski GP. Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer. J Gastrointest Surg. 1999; 3: 411-417.
  • 27
    Albo D, Rothman VL, Roberts DD, Tuszynski GP. Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor. Br J Cancer. 2000; 83: 298-306.
  • 28
    Castle V, Varani J, Fligiel S, Prochownik EV, Dixit V. Antisense-mediated reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma. J Clin Invest. 1991; 87: 1883-1888.
  • 29
    Qian X, Rothman VL, Nicosia RF, Tuszynski GP. Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production. Pathol Oncol Res. 2001; 7: 251-259.
  • 30
    Tuszynski GP, Nicosia RF. The role of thrombospondin-1 in tumor progression and angiogenesis. Bioessays. 1996; 18: 71-76.
    Direct Link:
  • 31
    Tuszynski GP, Nicosia RF. Localization of thrombospondin and its cysteine-serine-valine-threonine-cysteine-glycine-specific receptor in human breast carcinoma. Lab Invest. 1994; 70: 228-233.
  • 32
    Wakiyama T, Shinohara T, Shirakusa T, John AS, Tuszynski GP. The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer. Histol Histopathol. 2001; 16: 345-351.
  • 33
    Tobita K, Kijima H, Dowaki S, et al. Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma. Int J Oncol. 2002; 21: 1189-1195.
  • 34
    Wang TN, Qian X, Granick MS, et al. Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer. J Surg Res. 1996; 63: 39-43.
  • 35
    Qian X, Wang TN, Rothman VL, Nicosia RF, Tuszynski GP. Thrombospondin-1 modulates angiogenesis in vitro by up-regulation of matrix metalloproteinase-9 in endothelial cells. Exp Cell Res. 1997; 235: 403-412.
  • 36
    Bloomston M, Zervos EE, Rosemurgy ASII. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol. 2002; 9: 668-674.
  • 37
    John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res. 2001; 7: 14-23.
  • 38
    Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res. 1994; 54: 6504-6511.
  • 39
    Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol. 1995; 130: 503-506.
  • 40
    Roth JJ, Albo D, Rothman VL, et al. Thrombospondin-1 and its CSVTCG-specific receptor in wound healing and cancer. Ann Plast Surg. 1998; 40: 494-501.
  • 41
    Arnoletti JP, Albo D, Jhala N, et al. Computer-assisted image analysis of tumor sections for a new thrombospondin receptor. Am J Surg. 1994; 168: 433-436.
  • 42
    Lambert E, Dasse E, Haye B, Petitfrere E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol. 2004; 49: 187-198.
View Full Article (HTML) Get PDF (626K)